The labyrinthine world of international trade, particularly the fluctuating tariff policies enacted by the Trump administration, has created significant disruptions across various business sectors. The dietary supplement industry and its crucial supply chain for ingredients are no exception, experiencing a period of unprecedented volatility that is impacting production, quality, and consumer trust. From the vast botanical fields of India to the formulation labs of American supplement manufacturers, the ripple effects of these "topsy-turvy tariffs" are being felt acutely.
A "Roller Coaster Ride" of Uncertainty
For Suresh Lakshmikanthan, Chief Business Officer at Natural Remedies, an Indian company specializing in Ayurvedic botanicals, the year 2025 has been a tumultuous journey. "It has been a roller coaster ride the whole of 2025," Lakshmikanthan stated, reflecting on the constant shifts in trade policy. "The tariffs have had a significant impact on our production plan, our supply chain, our contracts with the growers, and also the customers who are formulating the product." This sentiment is echoed by many within the ingredient and supplement manufacturing sectors, where the ability to plan and forecast has been severely hampered by the unpredictable nature of these trade measures.
The consequences extend beyond mere logistical challenges. Ingredient and supplement companies are reporting that the tariffs are even beginning to affect product quality. As the cost of sourcing ingredients rises due to import duties, some companies are reportedly seeking cheaper alternatives or reformulating their products to include lower concentrations of high-potency, and consequently higher-cost, ingredients. This shift, driven by economic pressures, raises concerns about the efficacy and perceived value of supplements in the eyes of consumers.
The Indian Case Study: A Microcosm of Global Trade Dynamics
India, a significant global supplier of botanical ingredients and finished supplements, serves as a compelling case study for the profound impact of these tariff changes. According to reports from The Times of India, tariffs affecting goods between the U.S. and India have been in a state of near-constant flux since President Donald Trump took office.
The timeline of these fluctuations paints a vivid picture of the instability:
- April 2, 2025: Amidst ongoing U.S.-India trade negotiations, the U.S. initially imposed a substantial 26 percent tariff on Indian goods.
- A Week Later (Mid-April 2025): As discussions continued, this tariff was swiftly rolled back to a more moderate 10 percent.
- July 31, 2025: The rate surged again to 25 percent.
- A Week Later (Early August 2025): In response to India’s decision to purchase Russian oil, the U.S. doubled the tariff to a steep 50 percent, signaling a punitive measure within the broader trade relationship.
- February 2, 2026: Following India’s agreement to halt its Russian oil imports, the U.S. reduced the tariff rate to 18 percent.
- February 20, 2026: A pivotal moment arrived when the U.S. Supreme Court ruled that President Trump did not possess the unilateral authority to impose such tariffs. This decision effectively reduced the rate to zero.
- Subsequently: President Trump indicated his intention to explore alternative legal avenues to reintroduce tariffs, announcing plans for a 10 percent tariff to be applied to all countries.
This rapid and dramatic series of adjustments highlights the precariousness faced by businesses reliant on international trade. Each policy shift necessitates a re-evaluation of production schedules, sourcing strategies, and pricing models, creating an environment of perpetual uncertainty.
"Ridiculous" Unpredictability: The Achilles’ Heel of Trade Policy
For industry leaders like Shaheen Majeed, CEO and Managing Director of Sabinsa, an Indian company that produces a wide array of herbal extracts and specialty chemicals for various global industries, the sheer unpredictability of the tariff regime has been the most challenging aspect. "The most ridiculous thing was the unpredictability," Majeed stated emphatically.
Majeed elaborated on the operational paralysis caused by this uncertainty. If the U.S. were to impose a single, albeit high, tariff—even at the 50 percent rate India experienced at times—companies could adapt. They could make strategic decisions regarding their supply chains, negotiate with farmers for raw materials, or even consider relocating production to alternative countries. However, the constant flux means that any such strategic move could be rendered obsolete if the chosen alternative country also becomes subject to similar tariff disputes. This could lead to significant financial investments in strategies that ultimately fail.
Given this landscape, Sabinsa has adopted a strategy of maintaining its sourcing and production operations firmly within India, its home base. "The most ridiculous thing was the unpredictability," Majeed reiterated. "The most ridiculous thing was the unpredictability," Majeed said. "It’s where we produce. It’s where we do the agriculture." This commitment to domestic operations, despite the associated challenges, signifies a pragmatic approach to navigating the volatile trade environment. However, it also means absorbing the full brunt of high tariffs, a situation Majeed acknowledges has been "tough. No question."
Risking Customer Trust: The Perilous Path of Cost-Cutting
The escalating costs associated with tariffs have inevitably pushed many companies to explore ways to reduce their prices to remain competitive. Both Majeed and Lakshmikanthan caution that this pursuit of lower prices can come at a significant cost to brand reputation and customer loyalty.
Majeed pointed to the example of turmeric extract, a popular supplement ingredient. "All the studies that were done on turmeric extract really concentrated on the 95 percent assay," he explained. This high assay level, indicating near-pure curcuminoids, is widely recognized for its efficacy in supporting heart health, managing cholesterol and blood sugar levels, and mitigating inflammatory conditions. Manufacturers typically incorporate this potent form into their capsules, tablets, and gummies.
However, under the pressure of rising tariffs, Majeed has observed a concerning trend: "we’ve seen companies move into 20 percent assay material." He stressed that this lower concentration of active compounds significantly diminishes the product’s bioefficacy. Consumers, often unaware of the assay percentage, might see two bottles of turmeric extract priced differently—one at $20 and another at $11. The cheaper option, while financially attractive, may not deliver the expected health benefits.
The long-term implications of such compromises are severe. "You can lose a customer," Majeed warned. "And once you start losing a consumer to something like turmeric extract because ‘it didn’t work for me,’ that news spreads like wildfire, and that’s the last thing you need. You’re going to tell somebody, ‘Hey, I took that thing that didn’t work,’ and that person is going to tell somebody else. We don’t want that." This erosion of trust, he noted, is already becoming a reality in the market.
Lakshmikanthan corroborates this observation, noting that the ultimate consequence of these cost-cutting measures is a "trust deficit." While companies might achieve short-term sales gains, they risk alienating consumers in the long run. Furthermore, some companies are resorting to substituting cheaper synthetic products for the natural ingredients consumers expect. Lakshmikanthan emphasized Natural Remedies’ stance: "We encouraged our partners (not to do this)." He believes that American consumers, as the ultimate decision-makers, deserve products that meet efficacy standards. "The American consumers, they are the bosses," he asserted. "We want to make sure the product we give to American consumers is meeting their efficacy standards."
Stalled Innovation: The Impact on New Product Launches
For many companies, the introduction of new products is a critical driver of sales growth and market expansion. However, the prevailing pricing uncertainty stemming from tariff volatility has significantly hampered this innovation pipeline.
Lakshmikanthan highlighted that numerous brand customers who had planned new product launches have deferred their strategies due to the ambiguity surrounding future pricing. For instance, large companies intending to introduce new cognitive health and sleep-focused products in January 2026, a period that typically requires production to commence in October of the preceding year, have postponed their plans. "They all deferred," Lakshmikanthan said, waiting for clarity, particularly after the Supreme Court’s ruling on presidential tariff authority.
Consequently, the January 2026 quarter, usually a robust period for new product introductions, saw "no significant launch." This delay in bringing innovative products to market has a cascading effect, impacting not only the companies themselves but also the consumers who would have benefited from these advancements.
The initial impact of tariffs was somewhat buffered by existing inventory. Companies like Natural Remedies and Sabinsa had several months’ worth of product already in the U.S. market. However, as this inventory depleted, cash-flow challenges began to emerge. While well-capitalized companies could absorb the waiting period for sales, many businesses operate on tighter 30- or 60-day billing cycles, necessitating quicker revenue realization. "It affects your investment back into the business," Lakshmikanthan explained. "Some folks had a big challenge managing their cash flows."
The financial strain is particularly acute for suppliers who must pay tariffs upfront. Majeed described the process: "When a container comes in, it’s already sold." He has to remit payment to the government within 22 days, often exceeding $1 million for a substantial shipment. Subsequently, he extends credit to his customers, who then have another 30 to 60 days to pay him. This extended payment cycle means he is "out of pocket" for a significant period, impacting his working capital and ability to reinvest in the business.
From "Just in Time" to "Just in Case": A Fundamental Supply Chain Shift
Over the past decade, the supplement industry, like many others, had largely embraced a "just in time" (JIT) manufacturing model. This approach focused on producing goods only as they were needed, minimizing inventory holding costs and aligning production with anticipated consumer demand and agricultural harvest cycles.
However, the unpredictable nature of tariffs has fundamentally disrupted this model. "With tariffs, the entire model on which this supply chain was built did not work," Lakshmikanthan stated. Businesses have been forced to pivot towards a "just in case" (JIC) inventory strategy. This involves holding larger buffer stocks to mitigate the risk of sudden tariff increases or supply chain disruptions. The question that looms large is: "What if the tariff changes? What happens to the inventory you’re carrying there?"
This shift necessitates increased warehousing costs and a more complex inventory management system. Both customers and suppliers have had to absorb a portion of the tariff costs, with Natural Remedies and other ingredient providers sharing the burden alongside their clients. Majeed expressed a wish that he could have stockpiled ingredients proactively as tariffs were being implemented. However, Sabinsa’s products are often pre-sold before they even reach U.S. shores. "When a container comes in, it’s already sold," he noted. The high demand for popular ingredients like turmeric, ashwagandha, and Boswellia meant that they were "just so fast-moving, we just couldn’t ever keep stock of it."
Conclusion: The Unseen Victims of Trade Wars
In the complex web of international trade disputes and tariff adjustments, Suresh Lakshmikanthan arrives at a somber conclusion: "In all of this back and forth with the tariffs, the biggest losers are the American consumers." While businesses have undoubtedly faced significant challenges and operational hurdles, the ultimate impact is felt by the end-users.
Consumers are not receiving the best value or the most innovative products. New product launches are delayed, and the efficacy of existing supplements may be compromised due to cost-driven reformulations. "They are unfortunately not getting the best deal," Lakshmikanthan stated. "The new products are dated. They’re not getting the latest technology or any new innovations."
The volatility in global trade policy, exemplified by the fluctuating tariffs impacting the supplement industry, underscores the intricate connections between international economics and everyday consumer goods. The pursuit of specific trade objectives has inadvertently created an environment of uncertainty that stifles innovation, erodes quality, and ultimately disadvantages the very consumers that these policies are often intended to serve. The long-term implications for consumer trust and the sustainable growth of the supplement sector remain a significant concern as businesses continue to navigate this unpredictable landscape.